Obesity Therapeutics
1. Imcivree patent expiration
Treatment: NA
IMCIVREE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9458195 | RHYTHM | Melanocortin receptor ligands |
Oct, 2027
(1 year, 7 months from now) | |
| US8039435 | RHYTHM | Melanocortin receptor ligands |
Aug, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11129869 | RHYTHM | Pharmaceutical compositions |
Jul, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-892) | Jun 16, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 25, 2025 |
| Orphan Drug Exclusivity(ODE-336) | Nov 25, 2027 |
| New Patient Population(NPP) | Dec 20, 2027 |
| Orphan Drug Exclusivity(ODE-402) | Jun 16, 2029 |
| Orphan Drug Exclusivity(ODE-508) | Dec 20, 2031 |
| Orphan Drug Exclusivity(ODE-509) | Dec 20, 2031 |
Drugs and Companies using SETMELANOTIDE ACETATE ingredient
NCE-1 date: 25 November, 2024
Market Authorisation Date: 25 November, 2020
Dosage: SOLUTION
More Information on Dosage
IMCIVREE family patents
2. Ozempic patent expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
Treatment: Method of treating type 2 diabetes mellitus; A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; An adjunct to die...
OZEMPIC's oppositions filed in EPO
OZEMPIC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO NORDISK | Acylated GLP-1 compounds |
Mar, 2026
(26 days from now) | |
| US8129343 | NOVO NORDISK | Acylated GLP-1 compounds |
Dec, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9486588 | NOVO NORDISK | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US8579869 | NOVO NORDISK | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(2 years ago) | |
| US8672898 | NOVO NORDISK | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US6899699 | NOVO NORDISK | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US12295988 | NOVO NORDISK | Semaglutide in medical therapy |
Oct, 2038
(12 years from now) | |
| US7762994 | NOVO NORDISK | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 8 months ago) | |
| US10335462 | NOVO NORDISK | Use of long-acting GLP-1 peptides |
Jun, 2033
(7 years from now) | |
| US8684969 | NOVO NORDISK | Injection device with torsion spring and rotatable display |
Oct, 2025
(4 months ago) | |
| US9108002 | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jan, 2026
(a month ago) | |
| US11097063 | NOVO NORDISK | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(4 months from now) | |
| US9775953 | NOVO NORDISK | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(4 months from now) | |
| US10376652 | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jan, 2026
(a month ago) | |
| US8920383 | NOVO NORDISK | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(4 months from now) | |
| US10357616 | NOVO NORDISK | Injection device with an end of dose feedback mechanism |
Jan, 2026
(a month ago) | |
| US9861757 | NOVO NORDISK | Injection device with an end of dose feedback mechanism |
Jan, 2026
(a month ago) | |
| US9616180 | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jan, 2026
(a month ago) | |
| USRE46363 | NOVO NORDISK | Dial-down mechanism for wind-up pen |
Aug, 2026
(5 months from now) | |
| US9457154 | NOVO NORDISK | Injection device with an end of dose feedback mechanism |
Sep, 2027
(1 year, 7 months from now) | |
| US9687611 | NOVO NORDISK | Injection device with torsion spring and rotatable display |
Feb, 2027
(1 year, 5 days from now) | |
| US11311679 | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jan, 2026
(a month ago) | |
| US11446443 | NOVO NORDISK | Injection device with torsion spring and rotatable display |
Oct, 2025
(4 months ago) | |
| US10220155 | NOVO NORDISK | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(4 months from now) | |
| US8114833 | NOVO NORDISK | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(6 months ago) | |
| US9132239 | NOVO NORDISK | Dial-down mechanism for wind-up pen |
Feb, 2032
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
| New Dosing Schedule(D-185) | Mar 28, 2025 |
| New Indication(I-961) | Jan 28, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 06 October, 2022
Dosage: SOLUTION
How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage
OZEMPIC family patents
3. Victoza patent
expiration
Treatment: A method for improving glycemic control in adults with type 2 diabetes mellitus; Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults...
VICTOZA's oppositions filed in EPO
VICTOZA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8114833 | NOVO NORDISK | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6458924 | NOVO NORDISK | Derivatives of GLP-1 analogs |
Aug, 2017
(8 years ago) | |
|
USRE41956 (Pediatric) | NOVO NORDISK | Dose setting limiter |
Jul, 2021
(4 years ago) | |
| US7235627 | NOVO NORDISK | Derivatives of GLP-1 analogs |
Aug, 2017
(8 years ago) | |
| US6268343 | NOVO NORDISK | Derivatives of GLP-1 analogs |
Aug, 2017
(8 years ago) | |
| USRE43834 | NOVO NORDISK | Injection syringe |
Jan, 2019
(7 years ago) | |
| US6004297 | NOVO NORDISK | Injection syringe |
Jan, 2019
(7 years ago) | |
| US8579869 | NOVO NORDISK | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(2 years ago) | |
|
US6268343 (Pediatric) | NOVO NORDISK | Derivatives of GLP-1 analogs |
Feb, 2023
(3 years ago) | |
|
US8579869 (Pediatric) | NOVO NORDISK | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(2 years ago) | |
| USRE41956 | NOVO NORDISK | Dose setting limiter |
Jan, 2021
(5 years ago) | |
| US8846618 | NOVO NORDISK | Stable formulation of modified GLP-1 |
Jun, 2022
(3 years ago) | |
|
US8846618 (Pediatric) | NOVO NORDISK | Stable formulation of modified GLP-1 |
Dec, 2022
(3 years ago) | |
| US9968659 | NOVO NORDISK | Liraglutide in cardiovascular conditions |
Jan, 2037
(10 years from now) | |
| US9265893 | NOVO NORDISK | Injection button |
Sep, 2032
(6 years from now) | |
| US7762994 | NOVO NORDISK | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 8 months ago) | |
|
US7762994 (Pediatric) | NOVO NORDISK | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(1 year, 2 months ago) | |
|
US9265893 (Pediatric) | NOVO NORDISK | Injection button |
Mar, 2033
(7 years from now) | |
|
US8114833 (Pediatric) | NOVO NORDISK | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(8 days ago) | |
|
US9968659 (Pediatric) | NOVO NORDISK | Liraglutide in cardiovascular conditions |
Jul, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| M(M-115) | Apr 06, 2015 |
| M(M-176) | Apr 22, 2019 |
| New Indication(I-750) | Aug 25, 2020 |
| New Patient Population(NPP) | Jun 17, 2022 |
| Pediatric Exclusivity(PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 17 December, 2021
Market Authorisation Date: 25 January, 2010
Dosage: SOLUTION
How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage
VICTOZA family patents
4. Xenical patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6004996 (Pediatric) | CHEPLAPHARM | Tetrahydrolipstatin containing compositions |
Jul, 2018
(7 years ago) | |
| US6004996 | CHEPLAPHARM | Tetrahydrolipstatin containing compositions |
Jan, 2018
(8 years ago) | |
Drugs and Companies using ORLISTAT ingredient
Market Authorisation Date: 23 April, 1999
Dosage: CAPSULE
More Information on Dosage
XENICAL family patents